Skip to main content
. 2016 Jun 14;6:27566. doi: 10.1038/srep27566

Figure 6. The small molecule NQO1 inhibitor dicoumarol synergizes with rifampin for intracellular mycobacterial killing.

Figure 6

(A–C) THP1 cells were infected with BCG-Lux for 2 h and treated with 10 μM dicoumarol (DCM) alone or in combination with indicated concentrations of rifampin (RIF). Cells treated with media alone served as no treatment control. Intracellular mycobacterial growth was determined by taking daily luminescence readings in a 96-well plate luminometer and expressed as relative luminescence units (RLU). Shown are means ± SEM of 10–12 infections performed in three independent experiments. (D–F) Fold reduction was determined on day 5 after infection, and represents the number of times the bacterial RLU was decreased in the experimental compared to the untreated control. Fold reduction = 1/(RLU experimental/RLU control). Shown are means ± SEM of 10–12 infections performed in three independent experiments. Two-way ANOVA with the Tukey post-hoc method was carried out to determine significant differences between treatment groups. *p < 0.05, ***p < 0.001, ****p < 0.0001, ns = not significant.